Secondary efficacy analyses of the pivotal SEQUOIA-HCM trial continued to favor aficamten, supporting a potential role for ...

Global Commercial Launch Preparations Underway for First Potential Approval Towards Building Specialty Cardiovascular Franchise Company Recently Launched Unbranded Disease Awareness Campaign “HCM ...

武汉大学生命科学学院在读博士研究生赵闪及美国NIH国家医学图书馆Kira Makarova博士为该论文的共同第一作者，郑文超和刘雅菲等研究生深入参与了研究，杜世燊研究员与Eugene V.

“The Muscle: a Study in Biology and Pathology” (Exp. Sc. Fr., Paris, 1950). Schapira, G., Coursaget, J., Dreyfus, J. C., and Schapira, Mme F., 2nd International ...

An individual sarcomere contains many parallel actin (thin) and myosin (thick) filaments. The interaction of myosin and actin proteins is at the core of our current understanding of sarcomere ...

An established cardiac myosin inhibitor for hypertrophic cardiomyopathy (HCM), mavacamten (Camzyos) showed potential for ...

The biological needs of plants and animals affect their cells' protein content, but the story goes deeper than that.

Mavacamten, a drug initially developed to treat hypertrophic cardiomyopathy, has shown signs of reducing heart stress in ...

Purpose-driven marketing elevates brand-consumer relationships beyond transactional interactions. By linking brand values ...

Recently, a research group led by Prof. Miao Wei from the Institute of Hydrobiology (IHB) of the Chinese Academy of Sciences ...

Live imaging at single-vesicle resolution reveals rabphilin-3A as the first identified negative regulator of neuropeptide release in mammalian neurons.

In a report released today, Carter Gould from Barclays maintained a Buy rating on Cytokinetics (CYTK – Research Report), with a price ...